Latest Spasentain News 2024

April 30, 2024 Glomerular diseases have attracted significant attention from the nephrology industry over the past few years, driven in large part by the continued unmet needs of patients with these rare diseases. With a pipeline of approved products and a thriving pipeline, IgA nephropathy (IgAN) has become an innovation focus in the field. The latest milestone in this trajectory was the European Medicines Agency (EMA) announcement on April 24, 2024, of conditional approval of Travere/CSL Vifor’s sparsantane for the treatment of patients with primary IgAN with urinary protein excretion ≥1.0g/d (or urine protein to creatinine ratio ≥0.75g/g).

Results from the IgA Nephropathy (EU5) study reveal a dynamic landscape, as evidenced by analysis of 514 IgAN patient records collected in collaboration with 272 nephrologists in the UK, Germany, Italy, Spain and France. These data highlight the ongoing development of IgAN treatments, characterized by the increasing adoption of SGLT2 inhibitors and the use of Kinpeygo in Germany. Of note, EU5 physicians continue to seek to minimize the use of systemic corticosteroids and other immunosuppressants in this patient population, highlighting opportunities for new agents to further develop treatment modalities.

Despite increased use of SGLT2 inhibitors in early treatment, often in combination with ACE inhibitors and ARBs, approximately half of patients continue to have proteinuria levels above 1.0 g/day. This highlights the urgent need for new therapies to effectively improve patient outcomes. Additionally, there is growing demand for products that can significantly preserve kidney function, as doctors anticipate that most IgAN patients will eventually require dialysis.

In EU5 nephrologists surveyed in early 2024 said sparsentan had the highest level of familiarity among pipeline drugs in development for IgAN. As a groundbreaking non-immunosuppressive therapy on the verge of approval, sparsentan also had the highest patient candidate rate among patients reviewed, followed by atrasentan, ravulizumab (Alexion) and iptacopan (Novartis).

At this stage, sparsentin has not yet been launched in the domestic market, making it impossible for patients to purchase it directly from domestic channels. According to our understanding, the original research version of Sparsentan is sold overseas asThe price of 200 mg and 30 tablets is about 10,000 yuan, and may fluctuate with exchange rate changes. At the same time, Lucius Pharmaceuticals in Laos has also launched 400 mg of spaxentan in 30 tablets, with a price of about 7,800 yuan. If patients have more questions about sparsentane, please consult a medical consultant.